- Home
- RPGL vs CRIS Comparison
RPGL vs CRIS Comparison
Compare RPGL & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPGL | CRIS |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 14.6M |
| IPO Year | 2025 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RPGL | CRIS |
|---|---|---|
| Price | $0.57 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 29.5M | 114.6K |
| Earning Date | 02-16-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $2,364,485.00 | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | $38.62 | ★ N/A |
| Revenue Growth | ★ 339.01 | 13.56 |
| 52 Week Low | $0.23 | $1.02 |
| 52 Week High | $5.19 | $4.50 |
Technical Indicators
Market Signals| Indicator | RPGL | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 32.15 |
| Support Level | N/A | $1.02 |
| Resistance Level | N/A | $1.14 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 7.95 |
Price Performance
Historical ComparisonAbout RPGL Republic Power Group Limited Class A Ordinary Shares
Republic Power Group Ltd is a Singapore-based provider of customized software development, technology solutions, consulting, and technical support services. The company specializes in real-time monitoring, resource allocation, surveillance, and threat detection software, with capabilities in AI and IoT integration to provide services to corporate clients and government agencies.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.